Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques

Japanese Journal of Infectious Diseases

Volumn 65, Issue 4, 2012, Pages 345-349

  Nakasone, Tadashi ^a   Murakami, Tsutomu ^a   Yamamoto, Naoki ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; GENE DOSAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INFECTION PREVENTION; INFECTION RISK; LIMIT OF DETECTION; LYMPHOCYTE DEPLETION; MACACA; NONHUMAN; OUTCOME ASSESSMENT; PROPHYLAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA EXTRACTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIREMIA; VIRUS LOAD;

EID: 84866241589     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.65.345     Document Type: Article

References (43)

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS): INAIDS Report on the Global AIDS Epidemic 2010. Online at http://www.unaids.org/globalreport/default.htm
2. Editorial, The Lancet (2007): STEP study: disappointing, but not a failure. Lancet, 370, 1665.
3. Steinbrook, R. (2007): One step forward, two steps back-will there ever be an AIDS vaccine? N. Engl. J. Med., 357, 2653-2655.
4. Moore, J.-P., Klasse, P.-J., Dolan, M.-J., et al. (2008): AIDS/HIV. A STEP into darkness or light? Science, 320, 753-755.
5. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., et al. (2009): MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV infection in Thailand. N. Engl. J. Med., 361, 2209-2220.
6. Grant, R.-M., Buchbinder, S., Cates, W., Jr., et al. (2005): AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science, 309, 2170-2171.
7. Derdelinckx, I., Wainberg, M.-A., Lange, J.-M., et al. (2006): Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med., 3, e454.
8. Cohen, M.-S., Gay, C., Kashuba, A.-D., et al. (2007): Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV. Ann. Intern. Med., 146, 591-601.
9. Vissers, D.-C., Voeten, H.-A., Nagelkerke, N.-J., et al. (2008): The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One, 3, e2077.
10. Garcia-Lerma, J.-G., Otten, R.-A., Qari, S.-H., et al. (2008): Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med., 5, e28.
11. Garcia-Lerma, J.-G., Cong, M.-E., Mitchell, J., et al. (2010): In termittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci. Transl. Med., 2, 14ra4.
12. Garcia-Lerma, J.-G., Paxton, L., Kilmarx, P.-H., et al. (2010): Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol. Sci., 31, 74-81.
13. Cong, M.-E., Youngpairoj, A.-S., Zheng, Q., et al. (2011): Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J. Virol., 85, 7933-7936.
14. Abdool, Karim Q., Abdool, Karim S.-S., Frohlich, J.-A., et al. (2010): Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 329, 1168-1174.
15. Grant, R.-M., Lama, J.-R., Anderson, P.-L., et al. (2012): Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med., 363, 2587-2599.
16. Celum, C. and Baeten, J.M. (2012): Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr. Opin. Infect. Dis., 25, 51-57.
17. Shinohara, K., Sakai, K., Ando, S., et al. (1999): A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J. Gen. Virol., 80, 1231-1240.
18. Kaizu, M., Ami, Y., Nakasone, T., et al. (2003): Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV. Virology, 313, 8-12.
19. Nakasone, T., Sakai, K., Ami, Y., et al. (2002): Genetic and biological characterization of a highly pathogenic molecular clone, SHIV-C2/1 KS661. J. Med. Primatol., 31, 277.
20. Nakasone, T., Kanekiyo, M., Yoshino, N., et al. (2007): Cellassociated SHIV infection in cynomolgus monkeys. J. Med. Primatol., 36, 308-309.
21. Ami, Y., Izumi, Y., Matsuo, K., et al. (2005): Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol., 79, 12871-12879.
22. Murakami, T., Eda, Y., Nakasone, T., et al. (2009): Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+T-cell loss in macaque lymphoid tissue. AIDS, 23, 1485-1494.
23. Someya, K., Xin, K.-Q., Ami, Y., et al. (2007): Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys. Virology, 367, 390-397.
24. Motohara, M., Ibuki, K., Miyake, A., et al. (2006): Impaired Tcell differentiation in the thymus at the early stages of acute pathogenic chimeric simian-human immunodeficiency virus (SHIV) infection in contrast to less pathogenic SHIV infection. Microbes Infect., 8, 1539-1549.
25. Miyake, A., Ibuki, K., Enose, Y., et al. (2006): Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. J. Gen. Virol., 87, 1311-1320.
26. Matsuda, K., Inaba, K., Fukazawa, Y., et al. (2010): In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6. Virology, 399, 134-143.
27. Nakasone, T., Kumakura, S., Yamamoto, M., et al. (2012): Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study. Med. Microbiol. Immunol. doi:10.1007/s00430-012-0254-1
28. Pruvost, A., Negredo, E., Benech, H., et al. (2005): Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 49, 1907-1914.
29. Hawkins, T., Veikley, W. St., Claire, R.-L.IIIrd, et al. (2005): Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquired Immune Defic. Syndr., 39, 406-411.
30. Connor, R.-I., Sheridan, K.-E., Ceradini, D., et al. (1997): Change in coreceptor use correlates with disease progression in HIV-infected individuals. J. Exp. Med., 185, 621-628.
31. Xiao, L., Rudolph, D.-L., Owen, S.-M., et al. (1998): Adaptationto promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV disease progression. AIDS, 12, F137-143.
32. Esbjornsson, J., Månsson, F., Martfnez-Arias, W., et al. (2010): Frequent CXCR4 tropism of HIV subtype A and CRF02_AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology, 7, 23.
33. Huang, W., Eshleman, S.-H., Toma, J., et al. (2009): Vertical transmission of X4-tropic and dual-tropic HIV in five Ugandan mother-infant pairs. AIDS, 23, 1903-1908.
34. Raymond, S., Delobel, P., Mavigner, M., et al. (2010): Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J. Acquired Immune Defic. Syndr., 53, 167-175.
35. Archer, J., Braverman, M.-S., Taillon, B.-E., et al. (2009): Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV with ultra-deep pyrosequencing. AIDS, 23, 1209-1218.
36. Tsibris, A.-M., Korber, B., Arnaout, R., et al. (2009): Quantitative deep sequencing reveals dynamic HIV escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One, 4, e5683.
37. Tsibris, A.-M., Sagar, M., Gulick, R.-M., et al. (2008): In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol., 82, 8210-8214.
38. Westby, M., Lewis, M., Whitcomb, J., et al. (2006): Emergence f CXCR4-using human immunodeficiency virus type 1 (HIV) variants in a minority of HIV-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol., 80, 4909-4920.
39. Marx, P.-A., Spira, A.-I., Gettie, A., et al. (1996): Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med., 2, 1084-1089.
40. Sodora, D.-L., Gettie, A., Miller, C.-J., et al. (1998): Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res. Hum. Retroviruses (Suppl 1), S119-123.
41. Smith, S.-M., Baskin, G.-B. and Marx, P.-A. (2000): Estrogen protects against vaginal transmission of simian immunodeficiency virus. J. Infect. Dis., 182, 708-715.
42. Karim, S.-S. (2010): Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. Future Microbiol., 5, 527-529.
43. Supervie, V., Barrett, M., Kahn, J.-S., et al. (2011): Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci. Rep., 185, Epub 7 Dec 2011.